NCT00051181View on ClinicalTrials.gov

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2000

Primary Completion Date

June 30, 2003

Study Completion Date

June 30, 2003

Conditions
Glaucoma, Angle-ClosureOcular Hypertension
Interventions
DRUG

Travoprost (0.004%)

DRUG

Latanoprost (0.005%)

Trial Locations (2)

Unknown

Asia, Fort Worth

Australia, Sydney

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY